Drug-Eluting Stents Market Size, Share, Demand, Growth Analysis & Forecast Report 2024-2032

Summary:

• The global drug-eluting stents market size reached USD 8.3 Billion in 2023.
• The market is expected to reach USD 13.7 Billion by 2032, exhibiting a growth rate (CAGR) of 5.51% during 2024-2032.
• North America leads the market, accounting for the largest drug-eluting stents market share.
• Polymer-free coating accounts for the majority of the market share in the coating segment due to it’s more biocompatible and has a lower chance of negative reactions than conventional polymer-based coatings.
• On the basis of the drug, the market is segmented into sirolimus, paclitaxel, zotarolimus, everolimus, biolimus, and others.
• Cobalt-chromium remain a dominant segment in the market due to its superior strength, radiopacity, and advantageous mechanical characteristics, all of which improve stent performance and safety.
• Based on the generation, the market is classified into 1st generation, 2nd generation, 3rd generation, 4th generation.
• Hospitals accounts for the majority of the market share in the end-user segment because it serve as the main location for procedures involving drug-eluting stents, offering patients with cardiovascular diseases (CVD) comprehensive care.
• The increasing focus on patient-centric healthcare and personalized medicine is tailored to individual patient needs and specific cardiovascular conditions, thus supporting the market growth.
• Furthermore, the rise in regulatory approvals and favorable reimbursement policies for innovative CVD is enhancing market access and encouraging the adoption of drug-eluting stents in clinical practice.

Request to Get the Sample Report: https://www.imarcgroup.com/drug-eluting-stents-market/requestsample

Industry Trends and Drivers:

• Rising Prevalence of CVD:

One of the primary drivers of the drug-eluting stents (DES) market is the increasing prevalence of CVDs globally. CVDs, including coronary artery disease, heart attacks, and stroke, have become leading causes of morbidity and mortality worldwide. Factors such as sedentary lifestyles, unhealthy diets, obesity, smoking, and aging populations significantly contribute to the growing incidence of CVDs.

According to the World Health Organization (WHO), CVD are responsible for approximately 31% of global deaths, leading to an increasing demand for effective treatment options. Drug-eluting stents are designed to reduce the risk of restenosis by slowly releasing medication to inhibit cell proliferation and inflammation, aiding the market growth.

• Technological Advancements in Stent Design and Drug Delivery Systems:

Another significant factor driving the market is the continuous technological advancements in stent design and drug delivery systems. The evolution of stent technology has led to the development of more sophisticated DES with improved biocompatibility, reduced thrombogenicity, and enhanced drug elution characteristics.

Innovations such as biodegradable stents, which gradually dissolve over time, and new polymers that control drug release rates are enhancing the performance and safety of DES. Besides this, ongoing advancements in imaging technologies, such as optical coherence tomography (OCT) and intravascular ultrasound (IVUS), enable better visualization of the stent placement and post-procedural assessments, further strengthening the market growth.

• Increasing Awareness and Adoption of Minimally Invasive Procedures:

Percutaneous coronary interventions (PCIs) using DES have gained popularity due to their reduced recovery times, lower complication rates, and minimal hospital stays compared to traditional open-heart surgeries. Patients and healthcare providers are increasingly opting for less invasive alternatives that provide effective treatment with faster patient recovery.

This trend is bolstered by advancements in catheter-based techniques and better training for interventional cardiologists, leading to increased adoption of DES in clinical practice. As healthcare systems continue to prioritize patient-centered care and improved surgical outcomes, thereby providing an impetus to the market growth.

Speak to An Analyst: https://www.imarcgroup.com/request?type=report&id=4815&flag=C

Drug-Eluting Stents Market Report Segmentation:

Breakup By Coating:

• Polymer Based Coating
• Polymer Free Coating

Polymer-free coating accounts for the majority of shares due to its reduced risk of adverse reactions and improved biocompatibility compared to traditional polymer-based coatings.

Breakup By Drug:

• Sirolimus
• Paclitaxel
• Zotarolimus
• Everolimus
• Biolimus
• Others

On the basis of the drug, the market is segmented into sirolimus, paclitaxel, zotarolimus, everolimus, biolimus, and others.

Breakup By Stent Platform:

• Stainless-steel
• Cobalt-Chromium
• Platinum-Chromium
• Nitinol
• Others

Cobalt-chromium holds the majority of shares because of its excellent strength, radiopacity, and favorable mechanical properties that enhance stent performance and safety.

Breakup By Generation:

• 1st Generation
• 2nd Generation
• 3rd Generation
• 4th Generation

Based on the generation, the market is classified into 1st generation, 2nd generation, 3rd generation, 4th generation.

Breakup By Application:

• Coronary Artery Disease
• Peripheral Artery Disease

Coronary artery disease accounts for the majority of shares as it represents the most common indication for the use of drug-eluting stents in interventional cardiology procedures.

Breakup By End User:

• Hospitals
• Ambulatory Surgical Centers
• Others

Hospitals exhibit a clear dominance since they are the primary setting for procedures involving drug-eluting stents, providing comprehensive care for patients with cardiovascular diseases.

Breakup By Region:

• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

North America holds the leading position due to advanced healthcare infrastructure, higher rates of CVD, and significant investments in medical device technology and research.

Top Drug-Eluting Stents Market Leaders: The drug-eluting stents market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies.

Some of the key players in the market are:

• Abbott Laboratories
• B. Braun Melsungen AG
• Biosensors International Group Ltd.
• Biotronik
• Boston Scientific Corporation
• Cardinal Health Inc.
• Cook Medical LLC (Cook Group Incorporated)
• Lepu Medical Technology (Beijing) Co. Ltd.
• Medtronic plc
• MicroPort Scientific Corporation
• Sino Medical Sciences Technology Inc.
• Terumo Corporation.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email:?[email protected]

Tel No:?(D)?+91 120 433 0800

United States:?+1–631–791–1145